Sensorion, the French biotech that wants to restore babies' hearing, raises 50 million euros. Sensorion will thus be able to finance its research until 2025.
Last October, a little deaf boy regained his hearing after 11 years spent in complete silence. Aissam Dam is the first American patient to have his hearing treated with gene therapy. The biotech behind this feat is an American company, Akouos, bought in October 2022 by the American laboratory Elli Lilly for nearly $500 million. But France also has its nugget, which has been working for several years in this field.